Notification That Annual Report Will Be Submitted Late (nt 10-k)
July 03 2019 - 1:02PM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
One):
[X] Form
10-K
|
[ ] Form
20-F
|
[ ] Form
11-K
|
[ ] Form
10-Q
|
|
|
|
|
[ ] Form 10-D
|
[ ] Form N-SAR
|
[ ] Form N-CSR
|
|
For
Period Ended: March 31, 2019
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For
the Transition Period Ended:
Read
Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I
REGISTRANT
INFORMATION
Full
Name of Registrant
|
LUCKWEL
PHARMACEUTICALS INC.
|
|
|
Former Name if
Applicable
|
LUCKYCOM
PHARMACEUTICALS INC.
|
|
|
Address of Principal
Executive
|
|
|
|
Offices (Street
and Number)
|
303
Wyman St Suite 300
|
|
|
City, State and
Zip Code
|
Waltham, MA
02451
|
PART
II
RULE
12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check appropriate box)
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X]
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or
before the fifth calendar day following the prescribed due date; and
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion
thereof could not be filed within the prescribed time period.
(Attach extra sheets if needed.)
The
Company has encountered a delay in assembling the information, in particular its financial statements for the year ended March
31, 2019, required to be included in its March 31, 2019 Form 10-K Annual Report. The Company expects to file its March 31, 2019
Form 10-K Annual Report with the U.S. Securities and Exchange Commission within 15 calendar days of the prescribed due date.
PART
IV
OTHER
INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
Kingrich
Lee
|
|
(781)
|
|
728-0007
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months for such shorter period that the registrant was required to file
such report(s) been filed? If the answer is no, identify report(s).
[X]
Yes [ ] No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
[ ] Yes [X] No
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
LUCKWEL
PHARMACEUTICALS INC.
(Name
of Registrant as specified in charter)
Has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
By:
|
/s/
Kingrich Lee
|
Date: July 3, 2019
|
|
Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From Jul 2023 to Jul 2024